Journey Medical Corporation — Form 8-K Summary
Business Context and Reporting Period
Journey Medical Corporation, a specialty pharmaceutical company listed on Nasdaq under ticker DERM, filed a Form 8-K under Item 5.02. The event date was January 16, 2023; the report was signed and filed on January 20, 2023.
Management Change
- Ernest De Paolantonio resigned as Chief Financial Officer, effective January 27, 2023.
- Mr. De Paolantonio agreed to consult with and advise the company through March 31, 2023.
- Joseph Benesch, the company’s Corporate Controller since November 2021, was appointed interim CFO effective January 27, 2023.
- Mr. Benesch’s compensation did not change upon appointment. Any future changes are subject to Board determination upon Compensation Committee recommendation.
- Mr. Benesch is a certified public accountant with prior senior finance experience in specialty and generic pharmaceuticals and public accounting.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics.
Material Changes, Outlook, and Risks
The material disclosed change is the transition from a permanent CFO to an interim CFO. The filing does not state the reason for Mr. De Paolantonio’s resignation and does not identify any related financial impact, contingency, or change in business outlook.
The company reported that there are no family relationships between Mr. Benesch and its directors or executive officers, no selection arrangements or understandings involving his appointment, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Items
- Confirm the timing and completion of the CFO transition, including the end of Mr. De Paolantonio’s advisory period.
- Review subsequent filings for the appointment of a permanent CFO and any related compensation changes.
- Assess subsequent periodic reports for any financial or operational effects associated with the leadership transition.
- Review Exhibit 99.1, the related press release dated January 20, 2023.